Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDEMBRY vs PREGNYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
FDA: Treatment of prepubertal cryptorchidism,FDA: Induction of ovulation and pregnancy in anovulatory infertile women,Off-label: Hypogonadotropic hypogonadism in males,Off-label: Assisted reproductive technology (ART) protocols
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Terminal elimination half-life: 23–24 hours; clinically, supports daily or every-other-day dosing; peak effect may lag due to prolonged absorption
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal metabolism and excretion; limited hepatic metabolism.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Renal: 10-20% as unchanged drug; hepatic metabolism to inactive metabolites; fecal excretion negligible (<5%)
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~80% bound primarily to albumin; minor binding to sex hormone-binding globulin (SHBG)
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
0.5–0.7 L/kg; moderately distributed into extracellular fluid; penetrates gonadal tissues
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
Intramuscular: ~100%; Subcutaneous: comparable (~95-100%); Oral: <5% (not used)
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for prepubertal children; for delayed puberty in males: 1,000-2,000 IU intramuscularly 2-3 times weekly for 3-6 months.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
No specific recommendations; use lowest effective dose due to potential increased sensitivity and comorbidities.
None.
No FDA black box warning.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Ovarian hyperstimulation syndrome (OHSS) in women,Arterial thromboembolism,Precocious puberty in males,Fluid retention,Ovarian enlargement or cyst rupture
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
Hypersensitivity to h CG or any component,Premature epiphyseal closure in males,Androgen-dependent neoplasia (e.g., prostate cancer),Undiagnosed uterine bleeding,Ovarian cyst or enlargement due to polycystic ovarian syndrome (PCOS),Active thromboembolic disorders
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
No known clinically significant food interactions. Maintain usual diet unless advised otherwise by physician.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
Pregny (h CG) is not indicated for use during pregnancy. h CG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnormalities, but human data are insufficient. First trimester: No direct fetal risk from therapeutic use as it is discontinued before implantation. Second/Third trimester: Not used. Overall, classified as FDA Pregnancy Category X for ovulation induction (contraindicated in pregnancy) but no teratogenic risk if discontinued before conception.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
Human chorionic gonadotropin (h CG) is normally present in breast milk in low concentrations. Exogenous h CG is likely excreted into breast milk, but the M/P ratio is not established. Due to lack of data and potential for adverse effects in the infant (e.g., hormonal disruption), breastfeeding is not recommended during therapy. The manufacturer advises discontinuing breastfeeding or avoiding the drug.
Do not use in pregnancy. No dose recommendations available; contraindicated.
Pregny is contraindicated in pregnancy. No dose adjustment is applicable as it is discontinued prior to conception. There are no pharmacokinetic data for pregnancy, but the drug is not used during gestation.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Pregnyl (h CG) is used to trigger final follicular maturation and ovulation in assisted reproduction. Monitor for ovarian hyperstimulation syndrome (OHSS); consider withholding h CG if estradiol >4000 pg/m L or >20 follicles per ovary. Administer exactly 36 hours before oocyte retrieval. Intramuscular injection into gluteal muscle; rotate sites if repeated doses.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
Use Pregnyl exactly as prescribed to trigger ovulation; timing is critical for egg retrieval.,Report severe pelvic pain, bloating, nausea, or rapid weight gain (possible OHSS) immediately.,Avoid pregnancy tests during treatment as h CG may cause false positive.,May cause injection site pain or swelling; apply warm compress if needed.,Do not discontinue without consulting your fertility specialist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDEMBRY vs PREGNYL, answered by our medical review team.
ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. PREGNYL is a Gonadotropin Hormone that works by Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDEMBRY and PREGNYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. The standard adult dose of PREGNYL is: Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDEMBRY and PREGNYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. PREGNYL is classified as Category C. Pregny (hCG) is not indicated for use during pregnancy. hCG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.